Major Drug Companies Agree to Price Negotiations With U.S. Government
TUESDAY, Oct. 3, 2023 (HealthDay News) — Pharmaceutical companies that make the 10 prescription drugs chosen to be the first for price negotiations for Medicare patients have agreed to talks with the government.The Biden administration announced Tues…
Learn MoreMajor Drug Companies Agree to Price Negotiations With U.S. Government
TUESDAY, Oct. 3, 2023 (HealthDay News) — Pharmaceutical companies that make the 10 prescription drugs chosen to be the first for price negotiations for Medicare patients have agreed to talks with the government.The Biden administration announced Tues…
Learn MorePanel de la FDA rechaza medicamento experimental para Esclerosis Lateral Amiotrófica
VIERNES, 29 de septiembre de 2023 (HealthDay News) – Un panel asesor de la Administración de Alimentos y Medicamentos de EE. UU. (FDA, por sus siglas en inglés) votó el miércoles de manera contundente en contra de recomendar un tratamiento experimenta…
Learn MoreTezepelumab Reduces Mucus Plugs in Adults With Uncontrolled Asthma
FRIDAY, Sept. 29, 2023 (HealthDay News) — Tezepelumab is associated with a reduction in occlusive mucus plugs versus placebo in adults with uncontrolled asthma, according to a study published in the October issue of NEJM Evidence.Lars H. Nordenmark, …
Learn MoreSelf-Administered Etripamil Safe, Effective for Paroxysmal Supraventricular Tachycardia
FRIDAY, Sept. 29, 2023 (HealthDay News) — Investigational etripamil nasal spray is well tolerated for self-treating recurrent episodes of paroxysmal supraventricular tachycardia (PSVT) without medical supervision, according to a study published onlin…
Learn MoreFDA Panel Says No to Experimental ALS Drug
THURSDAY, Sept. 28, 2023 (HealthDay News) — An advisory panel to the U.S. Food and Drug Administration on Wednesday voted resoundingly against recommending a stem cell-based experimental treatment for amyotrophic lateral sclerosis (ALS).Although the …
Learn MoreRacial, Ethnic Differences Seen for Benefits of Antihyperglycemic Agents
THURSDAY, Sept. 28, 2023 (HealthDay News) — There are racial/ethnic differences in the cardiorenal effects of sodium-glucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 receptor agonists (GLP1-RAs) in patients with type 2 diabet…
Learn MoreFDA Panel Says No to Experimental ALS Drug
THURSDAY, Sept. 28, 2023 (HealthDay News) – An advisory panel to the U.S. Food and Drug Administration on Wednesday voted resoundingly against recommending a stem cell-based experimental treatment for ALS.Although the FDA isn’t bound by the votes of i…
Learn MoreFDA Adds Warning to Ozempic Label About Risk for Blocked Intestines
WEDNESDAY, Sept. 27, 2023 (HealthDay News) — Ozempic will now be labeled as having the potential to block intestines. The U.S. Food and Drug Administration recently made the label update for the drug made by Novo Nordisk, without directly citing Ozem…
Learn MoreBoth Ciclosporin, Methotrexate Effective for Severe Eczema in Children
TUESDAY, Sept. 26, 2023 (HealthDay News) — For children and young people with severe atopic dermatitis (AD), ciclosporin (CyA) and methotrexate (MTX) are both effective over 36 weeks, according to a study published online Sept. 19 in the British Jour…
Learn More